Back to Test Catalogue

Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies, CSF

Test ID: MOG CSF

Test

Aliases/Synonyms

Anti-MOG; MOG Antibodies

Method

Cell-Based Indirect Immunofluorescence

Method Description

This specific and sensitive cell-based assay is based on transfected cells expressing the full-length human MOG as target antigen.

Report Includes

Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)

Specimens

CSF

Clinical Utility

Many cases of Neuromyelitis Optica-spectrum disorders (NMOSD) are misdiagnosed as Multiple Sclerosis. As correct diagnosis is critical for prognosis, optimal treatment and prediction of relapse, initial testing for both Aquaporin 4 (AQP4) Antibodies and Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies is strongly recommended for new cases of NMOSD – see separate test listings. AQP4 antibodies are detected in about 80% of patients with NMO. Of these seronegative AQP-4 cases 7% will harbor MOG antibodies. Patients very rarely harbour both antibodies.

Test Location

St. Joseph's Hospital, 30 The Queensway, Toronto ON M6R 1B5

Test Version

15-Nov-2023

Specimen

Specimens

CSF

Sample Volume

1 mL

Minimum Volume

0.5 mL

Collection & Handling

Handling Information

Store and send frozen.

Stability

Ambient 6 hours
Refrigerated 14 days
Frozen 60 days

Test Version

15-Nov-2023

Performance / Interpretation

Method

Cell-Based Indirect Immunofluorescence

Method Description

This specific and sensitive cell-based assay is based on transfected cells expressing the full-length human MOG as target antigen.

Turnaround Time

9 days

Results

Name Units Reference Range Conversion Factor
Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)
  • Negative
Results of 1+ to 4+ indicate the presence of this autoantibody in increasing titers

Test Location

St. Joseph's Hospital, 30 The Queensway, Toronto ON M6R 1B5

Test Version

15-Nov-2023

Interface / Setup

HL7 Interface Codes

Order Code Result Codes Units
MOG CSF 62784Anti MOG (CSF)

Test Version

15-Nov-2023